evidence suggesting superiority of tocilizumab monotherapy Methotrexate monotherapy is conditionally recommended over dual or triple csDMARD therapy for DMARD-naive patients with moderate-to-high disease activity The recommendation favors methotrexate monotherapy because the higher burden of combination therapy (e.g., multiple medications, higher cost) outweighs the moderate-quality evidence suggesting greater improvements in disease activity associated with combination csDMARDs Methotrexate